In Industry News

The PRAC’s November meeting (27th – 30th) saw a host of topics discussed, including:

  • The commencement of a review of Esmya (ulipristal acetate), a medicine used to treat uterine fibroids.

 

  • The recommendation that modified- or prolonged-release paracetamol-containing medicines should be suspended from the market.

 

  • The PRAC also adopted a revision to its strategy to measure the impact of pharmacovigilance activities (originally launched in 2016).

The full meeting highlights are available on the EMA website here

 

 

 

Recent Posts